EC
ABUS icon

EntryPoint Capital’s Arbutus Biopharma ABUS Stock Holding History

EntryPoint Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$496K Buy
110,123
+34,516
+46% +$151K 0.15% 255
2025
Q4 		$364K Buy
75,607
+46,743
+162% +$210K 0.14% 282
2025
Q3 		$131K Sell
28,864
-32,241
-53% -$118K 0.05% 605
2025
Q2 		$189K Buy
61,105
+42,375
+226% +$141K 0.09% 496
2025
Q1 		$65.4K Buy
+18,730
New +$62.5K 0.03% 638

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

EntryPoint Capital's ABUS Position: Q1 2026 in Review

EntryPoint Capital increased its Arbutus Biopharma (ABUS) stake by 46% in Q1 2026, buying an estimated $151K and bringing the position to 110,123 shares worth $496K. The position accounts for 0.15% of the portfolio, ranked #255.

EntryPoint Capital first reported a position in ABUS in Q1 2025 and has held it in 5 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • EntryPoint Capital held 110,123 shares of Arbutus Biopharma worth $496K as of Q1 2026.
  • EntryPoint Capital bought 34,516 Arbutus Biopharma shares in Q1 2026, an estimated $151K.
  • Arbutus Biopharma made up 0.15% of EntryPoint Capital's portfolio in Q1 2026, its #255 holding.
  • EntryPoint Capital first reported a position in Arbutus Biopharma in Q1 2025 and has held it in 5 quarters since.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.